Whitepapers , Modified Release , Formulation Development , Translational Pharmaceutics

Alternative Strategies for Development of Modified Release Dosage Forms

Overview

Modified-release (MR) formulations are in high demand in today's drug development strategies.

For formulators, they enable drugs to be released in the optimal gastrointestinal (GI) locations to achieve and maintain desirable plasma concentrations for extended periods, avoiding undesirable excursions outside the therapeutic range.

Learn more about our capabilities for modified-release.

 

Types of modified-release dosage forms we work with:

Modified-release formatObjectiveFormulation technology
Gastro-retention
  • Keep the formulation in the stomach for an extended period to maximize the duration of absorption or therapeutic activity
Swellable tablets (monolithic, bilayer, trilayer)
Gastro-resistant
  • Prevent release of the drug in the stomach and/or upper gastrointestinal (GI) tract
  • Overcome first-pass metabolism or gastric irritation
Enteric-coated tablets or capsules
Sustained or extended release
  • Extend the in-vivo release profile of the drug or enable once-daily dosing
Matrix tablets, coated tablets, or multiparticulates
Targeted or controlled delivery
  • Release the drug at or near the intended site of absorption or action
  • Have either immediate-release or extended-release characteristics
  • Deliver time-, pH-, or microbially-triggered release
Tablets, capsules, or multiparticulates
Biphasic release
  • Eliminate the need for repeat dosing
  • Provide rapid therapeutic effect from an immediate-release layer and extended dosing from a sustained-release layer
Bilayer tablets or multiparticulates
Pulsatile release
  • Release the drug as a pulse after a pre-determined lag time, designed according to the body’s circadian rhythm
  • Provide a release mechanism beneficial for drugs where time-dependent dosing is required or those that undergo first-pass metabolism
Bilayer tablets or multiparticulates
Download
Ask The Experts

Solubility enhancement questions? Get answers from our team.

Have a question about your poorly soluble molecule? Ask a member of our team about our capabilities for drug product formulation, clinical or commercial manufacturing to keep your drug program on-track.

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Dr. Asma Patel

VP, Global Commercial and Scientific Consulting - Drug Product

Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...

About Asma
Robert Cornog

Senior Director, Product Development

Robert Cornog has over 26 years of experience in product development and process design. Across a broad range of dosage forms and ...

About Robert
Brad Rowe

Senior Director, Integrated Development

Brad Rowe joined the organization in 2005 and is based from our Philadelphia, PA sites in Garnet Valley and Boothwyn. He joined QS...

About Brad
Let's Talk
Humanity can't wait, so neither can we. Discuss your drug program today.